Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, it reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. It is approved by Health Canada for the treatment of type 2 diabetes.
Brand Name : Forxiga-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?